Cargando…

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China

OBJECTIVE: This study assessed the long-term cost-effectiveness of saxagliptin+metformin (SAXA+MET) versus acarbose+metformin (ACAR+MET) in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone. METHODS: Systematic literature reviews were performed to identify st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Shuyan, Zeng, Yuhang, Yu, Demin, Hu, Xiaoqian, Dong, Hengjin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119856/ https://www.ncbi.nlm.nih.gov/pubmed/27875596 http://dx.doi.org/10.1371/journal.pone.0167190

Ejemplares similares

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis
por: Gu, Shuyan, et al.
Publicado: (2015)

Cognitive and physical function of people older than 80 years in China from 1998 to 2014
por: Hu, Xiaoqian, et al.
Publicado: (2018)

Comparison of Glucose-Lowering Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Gu, Shuyan, et al.
Publicado: (2022)

Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis
por: Gu, Shuyan, et al.
Publicado: (2020)

Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
por: Bekele, Mengistu, et al.
Publicado: (2021)

The Quality of Caregivers for the Elderly in Long-Term Care Institutions in Zhejiang Province, China
por: Zeng, Yuhang, et al.
Publicado: (2019)

Impact of baseline characteristics on glycemic effects of add‐on saxagliptin or acarbose to metformin therapy: Subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus
por: Fang, Hui, et al.
Publicado: (2020)

Osteoarthritis in the Middle-Aged and Elderly in China: Prevalence and Influencing Factors
por: Sun, Xueshan, et al.
Publicado: (2019)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

Modeling the Cost-effectiveness of Esophageal Cancer Screening in China
por: Li, Yuanyuan, et al.
Publicado: (2020)

Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis
por: Sun, Xueshan, et al.
Publicado: (2021)

Outpatient health-seeking behavior of residents in Zhejiang and Qinghai Province, China
por: Huang, Minzhuo, et al.
Publicado: (2019)

Measurement and analysis of equity in health: a case study conducted in Zhejiang Province, China
por: Sun, Xueshan, et al.
Publicado: (2018)

Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis
por: Gu, Shuyan, et al.
Publicado: (2022)

Trends in Cognitive Function Among Chinese Elderly From 1998 to 2018: An Age-Period-Cohort Analysis
por: Hu, Xiaoqian, et al.
Publicado: (2021)

Trends in activities of daily living disability among Chinese older adults from 1998 to 2018: an age-period-cohort analysis
por: Hu, Xiaoqian, et al.
Publicado: (2022)

A comparative study of catastrophic health expenditure in Zhejiang and Qinghai province, China
por: Zhen, Xuemei, et al.
Publicado: (2018)

Chinese Minority Perceives the Doctor-Patient Relationship Differently: A Cultural and Economic Interpretation
por: Yang, Qian, et al.
Publicado: (2019)

Social Determinants of Health-Related Quality of Life among Residents in Zhejiang and Qinghai, China
por: Gu, Yuxuan, et al.
Publicado: (2019)

Clinical and economic impact of methicillin-resistant Staphylococcus aureus: a multicentre study in China
por: Zhen, Xuemei, et al.
Publicado: (2020)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Acarbose is again on the stage
por: Altay, Mustafa
Publicado: (2022)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
por: Neumiller, Joshua J.
Publicado: (2014)

Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients
por: He, Ke, et al.
Publicado: (2014)

Insulin Glargine and Acarbose in the treatment of elderly patients with diabetes
por: Li, Jing, et al.
Publicado: (2019)

Predictors of acarbose therapeutic efficacy in newly diagnosed type 2 diabetes mellitus patients in China
por: Zhang, Rong, et al.
Publicado: (2022)

Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
por: Sharma, Morali D
Publicado: (2010)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012)

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Kulasa, Kristen, et al.
Publicado: (2010)

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
por: Konya, Hiroyuki, et al.
Publicado: (2014)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
por: Elgart, Jorge F, et al.
Publicado: (2013)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
por: Ott, Christian, et al.
Publicado: (2014)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
por: Jain, Rajeev
Publicado: (2015)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
por: Minze, Molly G., et al.
Publicado: (2013)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations
por: Rosak, Christoph, et al.
Publicado: (2012)

Exploration of suitable pharmacodynamic parameters for acarbose bioequivalence evaluation: A series of clinical trials with branded acarbose
por: Huang, Jie, et al.
Publicado: (2020)

Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II
por: Torre, Enrico, et al.
Publicado: (2020)

Potential gains in health-adjusted life expectancy from reducing four main non-communicable diseases among Chinese elderly
por: Hu, Xiaoqian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bosi046120t1ojpqm4j5fvtdiu